BridgeMD
New treatment option for Skin Cancer, Non-Melanoma
Official title Impact of Hypofractionated Radiotherapy Strategy After Surgery of Skin Carcinomas in Older Patients
ClinicalTrials.gov ID: NCT05794035
What this study is testing
- What it's testing
- Non-melanoma skin cancer (NMSC) incidence as well as morbidity rates are high in older patients. Surgery is the standard of care.
- Time commitment: about 5 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 70 and older
You may be able to join if
- Patients aged ≥ 70 years
- OMS 0-3
- Pathology confirmation of invasive SCC or BCC
- At least one of high-risk factors for recurrence (R0 but close margins, location/size, microscopic perineural invasion, recurrent primary disease...
- No indication of regional nodal RT
You likely can't join if
- Macroscopic incomplete resection of the primary tumor (≥ R1)
- Patient with severe dementia not allowing follow-up
- Any psychological, familial, sociological, geographical or logistical reasons that would prevent participation to surveillance during treatment and...
- Other active cancers in treatment
- Participation in another treatment study (therapeutic trial interfering with the study's endpoints)
- Patient on AME (state medical aid)
See the full eligibility criteria
- Patients aged ≥ 70 years
- OMS 0-3
- Pathology confirmation of invasive SCC or BCC
- At least one of high-risk factors for recurrence (R0 but close margins, location/size, microscopic perineural invasion, recurrent primary disease, immunosuppression, thickness including Breslow and Clark level...
- No indication of regional nodal RT
- No prior RT to the treated site
- Written consent from patient or his/her legal representative, trustworthy person or family member if the person is physically unable to give his or her written consent
- Life expectancy ≥ 6 months, as clinically estimated by the investigator in charge of enrolment
- No contraindication for surgery and RT after multidisciplinary board meeting evaluation
- Affiliated to a social security scheme
- Macroscopic incomplete resection of the primary tumor (≥ R1)
- Patient with severe dementia not allowing follow-up
- Any psychological, familial, sociological, geographical or logistical reasons that would prevent participation to surveillance during treatment and follow-up
- Other active cancers in treatment
- Participation in another treatment study (therapeutic trial interfering with the study's endpoints)
- Patient on AME (state medical aid)
- Persons deprived of their liberty by a judicial or administrative decision
The study team makes the final eligibility decision.
Where it's taking place
- Créteil, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 5 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 70 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Créteil, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.